FDA asks Biogen and Eisai to provide more data on subcutaneous Leqembi
Eisai and Biogen’s plan to bring a subcutaneous version of its Alzheimer’s drug Leqembi to market is facing a delay.
The FDA requested more information …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
